NCT06568614

An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-89894 (SYH2039) Tablets in Patients With Advanced Solid Tumors

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: BeOne Medicines · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to learn more about a new drug called BG-89894 (previously known as SYH2039). Researchers want to see if the drug is safe, how well people can tolerate it, how it moves through the body, and whether it shows any early signs of helping to treat cancer. The information gathered may help guide how future studies are designed. The entire study is expected to last about four years. People who join the study may receive treatment for around six months and will be followed for about 12 months after their treatment ends. The study plans to enroll participants over a three-year period.

Conditions

• Advanced or Metastatic MTAP-deleted Solid Tumors

Interventions

Type	Name	Description
DRUG	BG-89894	Administered orally

Timeline

• Start date: 2024-10-12
• Primary completion: 2026-04-30
• Completion: 2026-04-30
• First posted: 2024-08-23
• Last updated: 2026-03-27

Locations

20 sites across 3 countries: United States, Australia, China

Regulatory

• FDA-regulated drug study